This channel includes news on cardiovascular care delivery, including how patients are diagnosed and treated, cardiac care guidelines, policies or legislation impacting patient care, device recalls that may impact patient care, and cardiology practice management.
Any lingering fears about patients using online portals to get bonus medical attention for free should be largely quieted, albeit not completely silenced, by a new study conducted at New York University.
New federal limits on state-directed payments are set to cut Medicaid funding in most states. Hospitals are expected to bear the brunt since they account for the majority—84%, around $78B a year—of state-directed healthcare spends.
Either the stakeholders issuing the warnings overstated the risk of widespread closings—or COVID-era emergency funds succeeded in heading off a calamity of national proportions. Either way, patient access has taken a hit here and there.
Major TAVR policy changes appear to be on the way—should clinicians be excited or concerned? Leading U.S. medical societies are sharing their early reactions.
Valve-in-valve TAVR outperforms redo SAVR for the first six months after treatment, according to a new meta-analysis published in the American Journal of Cardiology. Then, however, things begin to shift.
At a time when patient assaults against nurses are reportedly on the rise, cases that invert the equation only reinforce the public’s perception that hospitals are chaotic places.
“We can reach tissues, bones and organs with high spatial precision that haven’t been reachable with light-based printing methods," one researcher explained.
The popular SGLT2 inhibitor, sold under the brand name Farxiga, is approved by the FDA to treat heart failure, type 2 diabetes and CKD. Recent data on its ability to affect the symptoms of heart failure patients have been inconsistent.
In its annual outlook report released this week, Fitch Ratings says the coming calendar year will probably strike much of the sector as “another make or break” period.